Glofitamab for Chinese adults with second-line relapsed or refractory diffuse large B‑cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study follows Chinese adults with relapsed or refractory diffuse large B‑cell lymphoma who are starting or have recently started a glofitamab-based regimen. Eligible participants must have histologically confirmed disease after one prior systemic therapy and either plan to receive glofitamab at consent or have begun it within 90 days before enrollment. The study collects routine clinical data on treatment responses, adverse events, and real-world outcomes without assigning or modifying standard clinical care. Enrollment occurs at major cancer centers in China and excludes people participating in other interventional trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed R/R DLBCL after one line of systemic therapy
* Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment

Exclusion Criteria:

* Participants who currently participate in or plan to participate in any interventional clinical trial

Where it's running

• Cancer Hospital Chinese Academy of Medical Sciences.
  Langfang, Hebei, China Recruiting
• Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center
  Tianjin, Tianjin Municipality, China Recruiting
• Peking University People's Hospital
  Beijing, China Recruiting
• Peking University Third Hospital
  Beijing, China Recruiting
• The First Bethune Hospital of Jilin University
  Changchun, China Recruiting
• West China Hospital of Sichuan University
  Chengdu, China Recruiting

Study contacts

• Study coordinator: Reference Study ID Number: ML45172 https://forpatients.roche.com/ No attachments to email below.
• Email: global-roche-genentech-trials@gene.com
• Phone: 888-662-6728 (U.S. and Canada)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

  A group of elderly patients with newly diagnosed diffuse large B-cell lymphoma will try a lighter chemotherapy approach using three targeted drugs to see if it works and is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07012980

• Combining radiation therapy with lenalidomide and glofitamab for treating relapsed DLBCL

  This study is testing a new treatment combining radiation therapy with lenalidomide and glofitamab to see if it helps people with relapsed diffuse large B-cell lymphoma who haven't responded to other treatments.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06651853

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Glofitamab combo vs Rituximab combo with chemo for relapsed/refractory DLBCL

  This study tests whether glofitamab with chemotherapy (JS203-GemOx) helps patients with relapsed or refractory DLBCL more than rituximab with chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT07808827

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• Hypofractionated Radiotherapy plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

  This study tests a combination therapy—hypofractionated radiotherapy with GM-CSF, pomalidomide, and glofitamab—for adults newly diagnosed with primary CNS DLBCL to see if it helps control the disease.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07749365

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.